Including Herceptin and Perjeta to chemotherapy elevated toxicity in sufferers with HER2+ gastric cancers.
Herceptin plus chemotherapy confirmed numerical enhancements in general survival (OS) and progression-free survival (PFS) for HER2-positive gastric and gastroesophageal junction (GEJ) cancers, though these advantages weren’t sustained following a change within the chemotherapy routine, in response to information from the part 2 INNOVATION trial, which have been offered on the 2025 American Society of Scientific Oncology (ASCO) Gastrointestinal Most cancers Symposium.
The most important pathological response price (mpRR) was 23.3% in sufferers who acquired chemotherapy alone (33 sufferers), 37% in those that acquired chemotherapy plus Herceptin (64 sufferers) and 26.4% amongst those that acquired chemotherapy together with Herceptin and Perjeta (pertuzumab; 64 sufferers). Investigators administered surgical procedure to 84.8%, 98.4% and 92.2% of sufferers in every respective arm.
When stratifying outcomes by the chemotherapy spine, the mpRR within the chemotherapy plus Herceptin/Perjeta, chemotherapy/Herceptin and chemotherapy alone arms, respectively, have been 12.5%, 16.7% and eight.3% when a cisplatin/Xeloda (capecitabine) or 5-flurorouracil spine was administered. With a spine of fluorouracil plus leucovorin, oxaliplatin and docetaxel (FLOT); folinic acid, fluorouracil and oxaliplatin (FOLFOX); or Xeloda/oxaliplatin (CAPOX), the respective mpRRs have been 37.9%, 53.3% and 33.3%.
Throughout the general inhabitants, the median PFS was not reached (NR) within the chemotherapy monotherapy and chemotherapy/Herceptin arms, that means that greater than half of sufferers have been alive with out illness development when this was assessed. As well as, information confirmed a median of three.32 years within the Herceptin/Perjeta plus chemotherapy arm. In contrast with chemotherapy alone, the danger of development or loss of life decreased with Herceptin/chemotherapy however elevated with the addition of Perjeta.
Stratified PFS outcomes confirmed 3-year charges of 57.1% within the chemotherapy alone arm, 64.2% within the chemotherapy/Herceptin arm and 50.4% within the Perjeta triplet arm earlier than investigators instituted a protocol modification that modified the chemotherapy spine to FLOT throughout the examine’s European websites. Following this protocol modification, the three-year PFS charges have been 68.4%, 65% and 53.3% in every respective arm.
The median OS was not reached throughout all 3 remedy arms within the general inhabitants, with 3-year charges of 75.6% when utilizing chemotherapy alone, 76.9% with the addition of Herceptin and 65.2% when including Herceptin and Perjeta. The chance of loss of life was numerically decrease with Herceptin/chemotherapy versus chemotherapy alone however greater with Herceptin/Perjeta plus chemotherapy.
Earlier than the trial modification concerning the chemotherapy spine, the three-year OS charges have been 78.6% utilizing chemotherapy alone, 83.6% when including Herceptin and 68.3% with the addition of Herceptin and Perjeta. The three-year OS charges following the modification have been 73.3%, 72.2% and 62.2%, respectively.
“The INNOVATION examine didn’t meet its main finish level. The mixture of chemotherapy plus [Herceptin] and [Perjeta] was related to greater toxicity and no benefit. [PFS] and [OS] have been numerically improved when including [Herceptin] to chemotherapy doublet, however not after the modification when sufferers acquired FLOT,” Dr. Anna Dorothea Wagner, a marketing consultant, senior lecturer and head of the Gastrointestinal Most cancers Clinic within the Division of Oncology on the College Hospital of Lausanne, Switzerland, said within the presentation.
“On the idea of its very excessive [mpRR], the addition of [Herceptin] to chemotherapy could also be thought-about, particularly when tumor downsizing is required to realize a healing resection,” she added.1
Investigators of this part 2 trial randomly assigned sufferers to obtain chemotherapy alone in arm A, chemotherapy plus Herceptin in arm B, or chemotherapy together with Herceptin and Perjeta in arm C. All sufferers acquired neoadjuvant and adjuvant chemotherapy consisting of CAPOX, modified FOLFOX6, FLOT, cisplatin/Xeloda, or 5-fluorouracil. Moreover, sufferers acquired perioperative Herceptin in arm B and perioperative Herceptin/Perjeta in arm C.
The trial’s main finish level was the mpRR, outlined because the proportion of sufferers with lower than 10% viable tumor cells following neoadjuvant remedy per central evaluate. Secondary finish factors included recurrence-free survival (RFS), PFS and OS.
Sufferers with HER2-positive gastric and GEJ adenocarcinoma amenable to gastrectomy or esophagectomy have been eligible for enrollment on the trial. Different necessities for examine entry included having 1B to three tumors and HER2 overexpression.
Of notice, 4 cycles of FLOT have been administered to 93.8%, 93.3% and 80.6% of the chemotherapy alone, chemotherapy/Herceptin and chemotherapy plus Herceptin/Perjeta arms, respectively. Wagner highlighted decrease charges of FLOT dose depth within the arm that acquired Perjeta, which included a median dose depth of 87.9% for oxaliplatin, 85.5% for docetaxel, 93.2% for folinic acid and 82% for 5-fluorouracil.
Extra efficacy findings confirmed that RFS and OS improved in sufferers who achieved a mpR in contrast with those that didn’t.
Notable grade 3 (extreme) unintended effects within the chemotherapy alone, chemotherapy/Herceptin and chemotherapy plus Herceptin/Perjeta arms, respectively, included diarrhea (5.9% versus 3% versus 26.1%) and neutrophil rely decreases (32.4% versus 21.2% versus 21.7%). There have been two affected person deaths within the chemotherapy/Herceptin arm attributable to neutropenia plus pneumonia and sepsis in a single affected person and postoperative biliary peritonitis in one other. Investigators famous two affected person deaths within the Perjeta arm, which included one attributable to neutropenic sepsis with mucositis and one attributable to huge cerebral ischemia after surgical procedure.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
Reference
“INNOVATION”: integration of trastuzumab (T), with or with out pertuzumab (P), into perioperative chemotherapy of HER-2 constructive abdomen most cancers: general survival outcomes. Dr. Anna Dorothea Wagner, et al. J Clin Oncol.
